| Abstrakt: |
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Laranjo as Director, Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated with RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed dose combination of Aerie product Rhopressa®, and widely prescribed PGA latanoprost. The RoclatanTM new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA) is expected to take place in the second quarter of 2018. Mr. Laranjo previously held related marketing positions at UCB, Inc. and Allergan, Inc. [ABSTRACT FROM PUBLISHER] |
